Skip to content
OpenCapital
Get started

Replimune Group REPL Lessee Operating Lease Liability Payments Due

Lessee Operating Lease Liability Payments Due at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's lessee operating lease liability payments due.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's lessee operating lease liability payments due?
Replimune Group (REPL) reported lessee operating lease liability payments due of $4.58M in Q4 2025.
How has Replimune Group's lessee operating lease liability payments due changed year-over-year?
Replimune Group's lessee operating lease liability payments due decreased by 18.0% year-over-year, from $5.59M to $4.58M.